Navigation Links
Scientists successfully treat new mouse model of inflammatory bowel disease
Date:3/6/2008

March 6, 2008 -- Researchers trying to improve cancer immune therapy have made an unexpected find: They've produced the most accurate mouse model to date of inflammatory bowel disease (IBD), a cluster of conditions that afflict approximately 1.4 million Americans with abdominal pain, constipation and diarrhea.

The two most common forms of IBD are Crohn's disease and ulcerative colitis (UC); in extreme cases, they can be fatal. The mouse model closely resembles the most serious form of human UC and is uniformly fatal. But scientists successfully treated the mice with a pair of broad-spectrum antibiotics, easing gut inflammation and increasing survival. The results, reported this week in Public Library of Science-Medicine, have researchers eager to follow up both in the clinic and the lab.

"The antibiotics we gave the mice were used individually in unsuccessful clinical trials as ulcerative colitis treatments, but now we have colleagues who are thinking of giving combined therapy an informal try," says co-senior author Thaddeus S. Stappenbeck, M.D., Ph.D., assistant professor of pathology and immunology and of developmental biology. "The antibiotics probably won't be a cure by themselves, but they may provide us with a potent new approach to combine with other therapies."

The mice may also allow scientists to learn which species of gut microorganisms are becoming embroiled in battles with host immune systems, triggering the symptoms of UC. That information could allow the development of stronger and more specific treatments.

Silvia Kang, a former graduate student in the laboratory of co-senior author Paul Allen, Ph.D., the Robert L. Kroc Professor of Pathology and Immunology, created the mouse model by crossbreeding two mouse lines they had developed for cancer immune therapy research. Each mouse line had one protein knocked out that restrained immune T cells from shifting into attack mode.

"The idea was to see if we could create super killer T cells we could use to attack tumors," says Allen. "But all the mice became sick early on, started to lose weight and we soon realized that they all had serious gastrointestinal issues."

Allen decided to consult with Stappenbeck, an expert in IBD.

"I've looked at quite a few proposed mouse models of IBD, and I recognized right away that this had the potential to be outstanding," says Stappenbeck. "The colons of the mice were incredible. They were filled with inflammatory T cells. We found the mice almost exactly replicated the most acute types of ulcerative colitis."

Unlike prior models of IBD, the mice consistently develop gastrointestinal problems within a short time period and at a predictable point in their lifespan. When researchers treated the mice at three weeks with the antibiotics ciprofloxacin and metronidazole, colon inflammation was reduced and the mice were able to gain weight and survive longer.

Scientists believe IBD results from the host immune system damaging the tissues of the gut while erroneously attacking food and gut microorganisms that aid food digestion. There are an estimated 500 different species of microbes living in the gut, so sorting out which species are being attacked by the immune system has been an imposing challenge.

The new model may significantly ease that challenge. Although the dual antibiotics used to treat the mice are broad-spectrum, they didn't sterilize the guts of the mice, suggesting that the treatment happened to eliminate the microorganisms causing IBD.

"We'd like to treat the mice and then reintroduce candidate microorganisms into their guts to see if this restarts the inflammatory reaction," says Stappenbeck.

Stappenbeck and Allen plan continued collaborative study of the model.


'/>"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University in St. Louis
Source:Eurekalert

Related biology news :

1. Genes hold the key to how happy we are, scientists say
2. Scientists uncover a novel mechanism that regulates carbon dioxide fixation in plants
3. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
4. Scientists discover how cigarette smoke causes cancer: Study points to new treatments, safer tobacco
5. Exeter scientists pour cold water on EU bird policy
6. Yale scientists create artificial cells that boost the immune response to cancer
7. Scientists unravel the genetic coding of the pea
8. Scientists discover giant fossil frog from hell
9. Advertisers, neuroscientists trace source of emotions in brain
10. Amazon corridors far too narrow, warn scientists
11. Dung happens and helps scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... MOINES, Iowa , Jan. 11, 2017 ... industry first with the release of its patent-pending calibration ... quickly and reliably perform calibrations, securely upload data logs ... flexibility for the customer. "Fighting drunk driving ... only for the public at large, but also for ...
(Date:1/4/2017)... the thousands of attendees at this year,s International Consumer Electronics Show (CES), ... measurement devices and services, will be featuring its new line of ULTRA ... special CES Exhibit Suite , the new upper arm and wrist ... WellnessConnected product platform.  Continue Reading ... ...
(Date:12/20/2016)... The rising popularity of mobility services ... stoking significant interest in keyless access systems. Following ... energy (BLE), biometrics and near-field communication (NFC) are ... wireless technologies in the automotive industry. This evolution ... systems opens the market to specialist companies such ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  Spherix Incorporated (Nasdaq: ... committed to the fostering of technology and monetization of ... patent infringement lawsuits. Anthony Hayes , ... 2017, we will continue to communicate with shareholders about ... and our due diligence on other patent assets that ...
(Date:1/23/2017)... 23, 2017  Alkahest Inc. ("Alkahest"), a biotechnology ... diseases and other age-related conditions, announced today that Sam ... Chief Medical Officer. In this role, Dr. Jackson ... at Alkahest and serve on the Executive Leadership ... as Executive Director at Dynavax, where he led the ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... ongoing endeavors to bring to market a pioneering medical device for the treatment ... signed an engagement contract with Emergo, a global regulatory consultancy that helps companies ...
(Date:1/20/2017)... , ... January 20, 2017 , ... The two newest ... treatment options for patients. Vironika, a spin out from The Wistar Institute, and Sanguis, ... lab space at 3624 Market Street. , Vironika is developing a treatment for ...
Breaking Biology Technology: